Santhera's AGAMREE Momentum Meets a German Price Cut Headwind

Santhera's H1 revenue nearly doubled to CHF 48.3M and its operating loss shrank, but an 8.5% German price cut in Q1 2027 threatens 2027 cash flow.

Santhera Pharmaceuticals is threading a familiar needle for a commercial-stage specialty pharma: scaling a flagship drug fast enough to outrun the cost of selling it. The Swiss company's latest disclosures show real progress on that front, alongside a reminder that European pricing pressure has not gone away.

A leaner operating profile

First-half figures released roughly three weeks ago revealed a business pulling its cost base into line. Revenue from customer contracts reached CHF 48.3 million, nearly double the CHF 24.0 million booked a year earlier. Just as striking, the operating loss narrowed to CHF 6.6 million from CHF 35.4 million in the prior-year period, while the net loss fell to CHF 21.5 million.

The swing reflects a shift in the company's center of gravity. Where earlier phases were dominated by development spending, Santhera is now leaning on distribution partnerships and an established commercial footprint to slow the pace of cash burn. AGAMREE® sits at the center of that effort, generating recurring revenue alongside related licensing and milestone income. Management said worldwide AGAMREE® sales, including partner revenue, topped USD 175 million in the second quarter — the fourth consecutive quarter above that mark.

Four of Europe's big five now covered

Commercialization across Europe's largest economies remains the strategic priority. AGAMREE is now available in four of the five biggest European markets, a reach made possible in part by pricing and reimbursement deals secured in Spain and Italy. Santhera is betting that deeper penetration into national health systems will keep demand for the therapy climbing.

That confidence underpins unchanged full-year guidance: total revenue of CHF 80 million to CHF 90 million for 2026. Hitting the range will require the sales momentum to hold through the back half of the year.

Cash steady now, tighter in 2027

On liquidity, Santhera expects cash reserves to stay broadly flat through year-end compared with the level recorded on September 30. The picture shifts in the first half of 2027, when the company has flagged a fresh outflow. Two forces drive it: planned investment in inventory build-up and a mandatory price reduction of roughly 8.5 percent in the German market starting in the first quarter of 2027.

That scheduled cut illustrates how demanding long-term specialty pharma commercialization in Europe has become. For Santhera, the answer is volume — ramping sales in newly opened markets quickly enough to offset the margin hit ahead.

Market response

Investors have taken a constructive view of the story so far. The stock closed Thursday at EUR 16.22, giving it a gain of 19 percent since the start of the year. With a market capitalization of EUR 246.78 million, the focus now is whether the reduction in operating losses carries through the second half — and how much of the coming German pricing pressure the top line can absorb.